Clinical trial · Observational
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy: A Prospective Longitudinal Cohort
NCT04305613CI-TRIAL-00096144CLARITYactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiotoxicity | — | UNRESOLVED | — |
| Lung Cancer Stage II | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Lung Cancer Stage III | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Radiation Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemoradiation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cohort
- description
- Patients with locally advanced non-small cell lung cancer
- interventionNames
- Other: Chemoradiation
Primary outcomes (9)
- measure
- High Sensitivity C-Reactive Protein
- timeFrame
- up to 12 months
- description
- Change in hsCRP from baseline
- measure
- Growth Differentiation Factor 15
- timeFrame
- up to 12 months
- description
- Change in GDF-15 from baseline
- measure
- Placental Growth Factor
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 18 years of age * Histologically confirmed or clinically diagnosed non-small cell lung cancer where the plan is for definitive treatment that includes radiation * Able to give written informed consent Exclusion Criteria: * Pregnant or breast-feeding * Prior treatment with anthracyclines * Radiation treatment not expected to involve any heart exposure as determined by treating provider * ECOG performance status greater than 2 * Vulnerable patients, including pregnant women and prisoners * Contraindication to rest/vasodilator stress PET/CT, including: asthma with ongoing wheezing at time of enrollment; known Mobitz Type II AV block, 3rd degree AV block, or sick sinus syndrom, without a pacemaker; systolic blood pressure less than 90mmHg; known hypersensitivity to Regadenoson and adenosine; profound sinus bradycardia (heart rate less than 40bpm).
References
Publications (0)
Data not yet available
No reference posted for this study.